

Lessons Learned

Melody Lin, Ph.D.

Deputy Director, Office for Human Research Protections
Director, International Activities

Taipei, Taiwan

November 2004

Objectives

- Procedures
- Recurrent Problems
- Lessons Learned

OHRP

Authority/Responsibility

- Assurances
- Education
- Oversight (Audit)

OHRP



Human Subjects
Compliance Oversight Procedures

Compliance Oversight Jurisdiction

- 45 CFR 46
- OHRP Approved Assurance

How An Investigation Gets Started

- Complaint(s)
 - PI, IRB Member, Subject, Private Citizen, etc.
- Self Reporting
 - Institution, PI
- Media
- Other Incident Report *
 - FDA Inspection
 - NIH Project Specific Violation (PSV) Report
 - Cooperative Group Audit

* Most Incident Reports Do Not Become A Compliance Case

Compliance Procedures

- Written Complaint(s)
- OHRP Initiates Inquiry
- OHRP Evaluation

Compliance Site Visit

Site Visiting

- OHRP Staff
- Consultants
- Specific Complaint
- Systemic Protections

Action

- Ensure subjects are protected
- Require corrective actions
- Recommend institution -
Wide education effort


Action

- Recommend Additional IRB Resources
- Restrict Assurance (Multiple Project Assurance-MPA)
- Postpone MPA Renewal
- Recommend Additional Action by Other HHS Offices

Annual Statistics

- 100 Cases
- 6 - 8 Project Specific Violations (PSV)
- 2 - 3 Multiple Project Assurance (MPA) Restrictions or Suspensions

OHRP Compliance Oversight Data



Recurrent Compliance Problems (1)

- IRB lacks sufficient information to make determinations
- Inadequate continuing review, or longer than 1 year
- Inadequate IRB review at convened meetings

Recurrent Compliance Problems (2)

- Contingent approval without subsequent re-review
- IRB meetings without a quorum
- IRB members with conflicts of interest
- Inadequate records, minutes, files, documentation, policies and procedures

Recurrent Compliance Problems (3)

- Inappropriate use of expedited review for new, continuing, and changes
- Failure to report unanticipated problems to IRB, IO, OHRP
- Failure or inadequate review of protocol changes
- Inappropriate use of exempt categories

Recurrent Compliance Problems (4)

- Deficient or inadequate informed consent documents
- Lack of diversity, expertise of IRB membership
- Overburdened IRB
- Inadequate IRB resources

JHU Research Suspension



Ellen Roche
24 years old

- Healthy volunteer in a asthma study
- Died on July 2, 2001
inhalation of a non-approved drug
- Lungs were destroyed
- Employed at Johns Hopkins University

OHRP Site Visit Plan

July 16 & 17, 2001

OHRP Site Visit

July 16 - 18, 2001

Site Visit Team

- 5 OHRP Staff
- 3 Consultants
- 1 FDA Representative

Suspension of Assurance

July 19, 2001

OHRP Findings

- IRB not given published toxicity information on the product
- The drug was not approved for human use, no IND
- Quality of the drug uncertain
- IRB inappropriately used expedited review

OHRP Findings

- IRB did not approve protocol changes
- Informed consent:
 - procedures inadequately described
 - failed to disclose drug status
 - inadequately disclose risks

OHRP Findings

- Inadequate IRB information for continuing review
- Inappropriate IRB minutes and backlog
- Some IRB members had conflicts of interest

OHRP Findings

- IRB overloaded, lacking staff
- IRB members in need of education

Actions Taken OHRP

- Suspended assurance, suspending all federally-sponsored research
- Required re-evaluation of protocols
- Requested a plan to restructure the system for protecting human subjects
- Required plan to educate IRB members, staff and researchers

Univ. of Michigan

Research Suspension

Univ. of Michigan

News Release

August 30, 2001

Internal Investigation

- Suspend Research Privileges
 - leading cancer surgeon
- Extensive Investigation
 - numerous regulatory infractions
 - five human clinical trials

Researcher

- Not allow to conduct human research
 - three years
 - retroactive to October 20, 2000
 - all human research suspended by IRB

Findings

- Breaches of IRB Rule
 - 5 trials
 - 94 research volunteers
 - frequent and pervasive
 - not adhere to federal and university rules

IRB Breaches

- Informed consent
 - obtain after study begin
 - inadequate documentation
- Deviation from the IRB approved protocol
- Patients enrolled after the study was closed
- Adverse events
 - not reported
 - not reported in a timely manner

Lessons Learned

- Strengthen Continuing Review
- SAE Reporting
- DSMB

Internal Investigations

vs.

OHRP/FDA Investigations

Lessons Learned

- Roles & Responsibilities
- Policies & Procedures
- Staff Training & Education
- System Adequacy

Lessons Learned

- Leadership
- Institutional Commitment

Proactive Prevention

vs.

Reactive Enforcement

Effective Monitoring

- Quality Improvement
- Continuing Education
- Commitment

Quality ↔ Compliance

- Quality Programs Enhance Compliance
- Compliance Programs Enhance Quality



Compliance

Quality

Shared Goals

Protecting Human Subjects

Promoting Ethical Research

Shared Responsibilities

- Investigators
- IRB (chair, members, administrator)
- Institutional CEO